What is the market price of dacomitinib/dacomitinib in 2024?

Dacomitinib (Dacomitinib) is a drug specifically used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body. It belongs to the kinase inhibitor drug family and can effectively block abnormal proteins that transmit proliferation signals to cancer cells, thereby helping to curb or block the spread of cancer cells.

As an oral medication, dacomitinib comes in tablet form and is generally recommended to be taken once daily at a scheduled time, with or without food. It is important that patients strictly abide by the doctor's instructions and should not increase or decrease the dosage or change the frequency of medication at will. If vomiting occurs after taking the medication, it is not recommended to take another dose immediately, but you should continue to follow the established medication plan. When certain side effects occur, the doctor may adjust the treatment plan based on the actual situation, including temporarily or permanently stopping the medication, or reducing the dosage. No matter how your body feels, taking your medication consistently and regularly is crucial.

It is gratifying that dacomitinib, an innovative drug, has been successfully launched in China and has been included in Class B medical insurance, which has significantly reduced the financial pressure on patients. The currently available specifications on the market are 15 mg and 30 tablets, which are priced at more than 1,000 yuan. For dacomitinib sold in overseas markets, especially in Europe, the price of 45 mg 30 tablets is relatively high, about more than 20,000 yuan. However, it should be noted that this price will fluctuate with changes in international exchange rates. Fortunately, there are also more reasonably priced generic drug options in overseas markets. For example, a 45mg*30 tablet version of dacomitinib made in Laos costs only about 800 yuan. Although its price will also be affected by exchange rate changes, its cost-effectiveness is still significant compared with original drugs.